Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 62175-302

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 62175-302). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of rabeprazole sodium, showing the arrangement of its atoms and bonds, including a benzene ring, sulfur atom, and other characteristic functional groups.*

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph depicting mean heartburn scores over a 28-day study period comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (None) to 4 (Very Severe). The graph shows a decrease in scores after day 0 for both Rabeprazole groups compared to placebo.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

A line graph showing mean heartburn scores over a 42-day period (14 days before and 28 days after study day 0) for three groups: Placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg. The vertical axis represents the mean score from 0 (none) to 4 (very severe), and the horizontal axis represents study days.*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group and a Rabeprazole Sodium 20 mg group. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph illustrates decreasing heartburn scores after day 0, with the Rabeprazole 20 mg group showing lower scores than placebo.*

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

A line graph comparing mean heartburn scores over a 28-day study period for placebo and Rabeprazole Sodium 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis displays mean scores ranging from 0 (None) to 4 (Very Severe). The solid line represents the Rabeprazole Sodium 20 mg group and the dashed line the placebo group.*

FDA Label Image

20 mg 30 Count Bottle Label (Rabeprazole Sodium Delayed Release Tablets 6)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Lannett Company, Inc. The label states each tablet contains 20 mg of rabeprazole sodium and includes storage instructions (25°C with permitted excursions). It indicates a package of 30 tablets with prescription use only. The label features the Lannett logo and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.